Alector Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Alector stock.
View analyst ratings for Alector or view top-rated stocks.

6 analysts have issued twelve-month price targets for Alector's stock. Their ALEC stock forecasts range from $6.00 to $57.00. On average, they anticipate Alector's share price to reach $29.86 in the next year. This suggests a possible upside of 178.3% from the stock's current price.
View analysts' price targets for Alector or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $20.65 at the beginning of the year. Since then, ALEC stock has decreased by 48.0% and is now trading at $10.73.
View the best growth stocks for 2022 here.

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alector.

Alector, Inc. (NASDAQ:ALEC) released its earnings results on Thursday, November, 4th. The company reported $1.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $1.95. The business earned $182.41 million during the quarter, compared to the consensus estimate of $407.41 million. Alector had a negative trailing twelve-month return on equity of 10.57% and a negative net margin of 12.65%.
View Alector's earnings history.

4 employees have rated Alector CEO Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alector include Abcam (ABCM), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Bavarian Nordic A/S (BVNRY), Twist Bioscience (TWST), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Allogene Therapeutics (ALLO), Krystal Biotech (KRYS), ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Exscientia (EXAI), Immunocore (IMCR) and Recursion Pharmaceuticals (RXRX).
View all of ALEC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (7.12%), Vanguard Group Inc. (6.53%), BlackRock Inc. (6.44%), State Street Corp (4.60%), JPMorgan Chase & Co. (2.95%) and Renaissance Technologies LLC (0.85%). Company insiders that own Alector stock include Arnon Rosenthal, Calvin Yu, David M Wehner, Orbimed Advisors Llc, Richard H Scheller, Robert King, Robert Paul, Sabah Oney, Shehnaaz Suliman and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Goldman Sachs Group Inc., Citigroup Inc., Vanguard Group Inc., Bank of America Corp DE, JPMorgan Chase & Co., PDT Partners LLC, and Pier Capital LLC. Company insiders that have sold Alector company stock in the last two years include Arnon Rosenthal, Calvin Yu, Richard H Scheller, Robert King, Robert Paul, and Shehnaaz Suliman.
View insider buying and selling activity for Alector or view top insider-selling stocks.

ALEC stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Massachusetts Financial Services Co. MA, Nantahala Capital Management LLC, and Raymond James & Associates.
View insider buying and selling activity for Alector or or view top insider-buying stocks.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALEC stock can currently be purchased for approximately $10.73.

Alector (NASDAQ:ALEC) has a market capitalization of $894.10 million and generates $207.09 million in revenue each year. The company earns $-36.33 million in net income (profit) each year or ($0.420010) on an earnings per share basis.

Alector employs 208 workers across the globe.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for Alector is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at [email protected].